PFAS exposure may limit improvements in blood sugar after bariatric surgeryPFAS exposure may limit improvements in blood sugar after bariatric surgery
A new USC study shows teens with higher blood levels of per- and polyfluoroalkyl substances (PFAS) measured before bariatric surgery had smaller improvements in blood sugar over five years, including fasting glucose and hemoglobin A1c (HbA1c), which measures average blood sugar levels over the past 60–90 days.
GLP-1RAs shown to reduce risk of cardiovascular deathGLP-1RAs shown to reduce risk of cardiovascular death
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed both for Type 2 diabetes and weight loss. These drugs also have shown promise in clinical trials for patients with chronic cardiovascular, kidney, and metabolic diseases. Those studies focused mainly on patients with singular diagnoses, but these conditions often overlap. Glucagon-like Read More
Antibody halts triple-negative breast cancer in preclinical modelsAntibody halts triple-negative breast cancer in preclinical models
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast cancers treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant than before.
New approach makes common breast cancer type responsive to immunotherapyNew approach makes common breast cancer type responsive to immunotherapy
A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common tumor type, estrogen receptor-positive or luminal breast cancer. This subtype accounts for 70% of breast cancer cases, and despite effective treatments, it causes the highest mortality in total cases.
GLP-1 receptor agonist use linked to chronic cough among adults with type 2 diabetesGLP-1 receptor agonist use linked to chronic cough among adults with type 2 diabetes
For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic cough, according to a study published online Nov. 26 in JAMA Otolaryngology-Head & Neck Surgery. For patients with type 2 diabetes, there is an association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and chronic Read More
Biomarkers link ER+ breast cancer to neighborhood povertyBiomarkers link ER+ breast cancer to neighborhood poverty
Scientists have long known that Black women with estrogen-receptor positive breast cancer and those who live in disadvantaged neighborhoods often have more aggressive forms of the disease and poorer survival rates. However, the underlying factors that link these outcomes with women’s living environments have remained unclear.
Alcohol Use, Lifestyle Factors Shape Breast Cancer RiskAlcohol Use, Lifestyle Factors Shape Breast Cancer Risk
(MedPage Today) — In this exclusive video ahead of the upcoming San Antonio Breast Cancer Symposium (SABCS), Seema Kahn, MD, of Northwestern University Feinberg School of Medicine in Chicago, previews her session on alcohol use, metabolism, and…
Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer’s, despite trial setbackNovo Nordisk still sees potential for GLP-1 drugs for Alzheimer’s, despite trial setback
Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing trials last month. Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing trials last month.
“Paw-zempic”: Could GLP-1 drugs work for obese cats?”Paw-zempic”: Could GLP-1 drugs work for obese cats?
Weight loss drugs for Americans have skyrocketed to success. Now, the GLP-1 frenzy could be heading to a new frontier: your pets. A San Francisco biopharmaceutical company says it is conducting a pilot study on a GLP-1 drug for cats with obesity. Okava CEO Michael Klotsman joins CBS News to discuss. Weight loss drugs for Read More
Spatial Omics May Transform the Future of Breast Cancer TreatmentSpatial Omics May Transform the Future of Breast Cancer Treatment
(MedPage Today) — In this exclusive video ahead of the upcoming San Antonio Breast Cancer Symposium (SABCS), Leif W. Ellisen, MD, PhD, of Harvard Medical School and Massachusetts General Hospital in Boston, previews his session on advances in…